PTCB Certified Pharmacy Technician (PTCE)Federal RequirementsMedium
A pharmacy technician is assisting a patient who is picking up a prescription for Clozapine. The patient mentions they are experiencing some unusual side effects and asks if there's anything special about this medication. The technician should recognize that Clozapine is part of a specific program designed to manage serious risks. Which type of program is this?
- AInvestigational New Drug (IND) program
- BRisk Evaluation and Mitigation Strategy (REMS) program
- CDrug Utilization Review (DUR) program
- DMedication Therapy Management (MTM) program
Show answer & explanationAnswer & explanation
Correct answer: B. Risk Evaluation and Mitigation Strategy (REMS) program
Clozapine is a medication with a known risk of severe neutropenia and other serious adverse effects, requiring a specific REMS program to ensure safe use. This program includes requirements for patient monitoring and prescriber/pharmacy certification.
Why the other options are wrong
- A. IND programs are for unapproved drugs undergoing clinical trials, not for approved drugs with specific risk management requirements.
- C. DUR programs review prescriptions for safety and appropriateness but are not specific drug-risk management programs.
- D. MTM programs focus on optimizing therapeutic outcomes for patients, not on managing inherent drug risks.
REMS Program (Clozapine)
A Risk Evaluation and Mitigation Strategy (REMS) program is an FDA-mandated strategy to manage a drug or biological product with a known or potential serious risk, ensuring that the benefits of the drug outweigh its risks. Clozapine has a REMS due to risks like severe neutropenia.
- FDA-mandated for drugs with serious risks.
- Clozapine REMS requires patient lab monitoring.
- Prescriber and pharmacy must be certified/enrolled.
Memory trick: REMS: Risks Evaluated, Mitigation Strategies enacted, Safe use Ensured.